Join Aiforia for their webinar on AI in lung cancer pathology PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology Date: Monday, June 23, 2025 Time: 3:00 p.m. CEST / 9:00 a.m. EDT Register to join live...

Aiforia is happy to announce the win of this contract award, which enables us to offer our AI solutions directly for 25 NHS Trusts pathology departments in the UK. Aiforia has received a contract award to provide artificial intelligence...

Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other...

Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis (PresseBox) (Hamburg, 06/09/2022) -- Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE...

Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical...

Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study finds A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered. In a landmark...